The Korea Institute of Science and Technology (KIST) and Neocannbio Co. Ltd. have jointly identified compounds acting as nitric oxide (NO) production inhibitors with potential for the treatment of inflammatory bowel disease (IBD).

Shanghai Aryl Pharmtech Co. Ltd. and Zhejiang Hisun Pharmaceutical Co. Ltd. have jointly identified Werner syndrome ATP-dependent helicase (WRN; RECQ3; RECQL2) inhibitors for use in the treatment of cancer.

F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have patented Myt1 kinase (PKMYT1) inhibitors for the treatment of cancer.

CHA University has identified chalcone derivatives acting as acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) inhibitors potentially useful for the treatment of Alzheimer’s disease.

Rongchang Pharmaceutical (Zibo) Co. Ltd. has synthesized nitrogen-containing fused ring compounds acting as glucagon-like peptide 1 receptor (GLP-1R) agonists potentially useful for the treatment of obesity and diabetes.

Dice Alpha Inc. has disclosed interleukin-17A (IL-17A) inhibitors designed for use in the treatment of psoriasis, rheumatoid arthritis, multiple sclerosis and more.

Work at Shionogi & Co. Ltd. has led to the discovery of fused-ring quinolone derivatives for the treatment of malaria.

Therapex Co. Ltd. has identified pyrimidine derivatives acting as EGFR (HER1; erbB1) mutant inhibitors described as potentially useful for the treatment of cancer.

Sumitomo Pharma Co. Ltd. has patented aminomethylcyclohexane derivatives acting as muscarinic M4 receptor antagonists. As such, they are described as potentially useful for the treatment of neurodegenerative diseases, cerebrovascular disorders, brain injury, movement and psychiatric disorders.

Frontier Medicines Corp. has divulged GTPase KRAS/PI3Kα interaction inhibitors. They are intended for use in the treatment of cancer.